Today: 13 July 2026
Oklo stock jumps again in premarket as Meta nuclear deal keeps OKLO in focus
12 January 2026
1 min read

Oklo stock jumps again in premarket as Meta nuclear deal keeps OKLO in focus

New York, Jan 12, 2026, 04:54 EST — Premarket

  • Oklo shares climbed roughly 8% in early premarket trading, building on last week’s surge.
  • Meta’s move into nuclear energy has spotlighted small-reactor developers and companies tied to the power grid.
  • Investors want clearer info on funding, permits, and timelines.

Shares of Oklo Inc jumped roughly 7.9%, reaching $105.31 in early premarket action on Monday.

The rally extends last week’s momentum, driven by renewed Big Tech interest in reliable power—a trend funneling capital into nuclear and its supply chain. Oklo’s appeal isn’t current output but the prospect of a long-term contract and a quicker route to funding.

Meta Platforms announced on Friday it has sealed 20-year deals to buy power from three Vistra nuclear plants and will collaborate with Oklo and TerraPower on small modular reactors (SMRs)—smaller, more easily replicated reactors compared to traditional large facilities. The agreements could supply up to 6.6 gigawatts of nuclear power by 2035. Joel Kaplan, Meta’s chief global affairs officer, called the move a step toward making Meta “one of the most significant corporate purchasers of nuclear energy in American history.” Oklo CEO Jacob DeWitte added that Meta’s backing will support “early procurement and development.” Reuters

Oklo announced its deal with Meta pushes ahead plans for a 1.2-gigawatt power campus in Pike County, Ohio. The agreement includes a provision for Meta to prepay for power and bankroll work to finalize the project details. Oklo plans to use these funds to secure nuclear fuel and advance Phase 1. DeWitte confirmed the company has completed the purchase of over 200 acres in Pike County.

Before the bell, other nuclear-related stocks climbed as well. Vistra jumped roughly 10.5%, while NuScale Power added around 4.3% in premarket action.

Insider selling has caught some investors’ attention following recent sharp rallies. A Form 4 filed Jan. 9 revealed that Oklo co-founder and COO Caroline Cochran sold shares on Jan. 7 and 8 under a Rule 10b5-1 plan, which allows pre-scheduled trades.

The story isn’t straightforward. Oklo must navigate regulatory hurdles before selling commercial power, and SMR projects face a slew of permitting and execution risks that often push timelines around.

Meta’s deals come amid growing pressure on an already stretched mid-Atlantic power grid, strained by new data centers. Jesse Jenkins, assistant professor of engineering at Princeton University, cautioned that launching Meta’s Prometheus project without adding fresh power supply “will only increase electricity rates across the mid-Atlantic grid.” AP News

Traders are now focused on whether Monday’s initial surge holds steady as liquidity picks up, or if the stock will slip back as investors shift away from the biggest winners.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Pfizer (NYSE:PFE) gets FDA nod for Padcev with Keytruda, stock dips
    July 12, 2026, 6:03 PM EDT. Pfizer (NYSE:PFE) picked up FDA approval for its Padcev and Keytruda combo in bladder cancer. The treatment cut recurrence or death risk by 47% in Phase 3. Even with trial data pointing to a therapy shift away from chemo, Wall Street didn't budge-shares slipped 0.33% after the news. Padcev brought in $165 million last quarter, making up 22% of revenue growth at Pfizer. Investors aren't buying in yet. They're still looking for signs this can fill the gap from patent losses. Doctors can now give the drug before and after bladder surgery, opening it to 25,500 U.S. muscle-invasive patients each year.
UiPath stock: CEO share sale filing puts PATH in focus ahead of a busy week
Previous Story

UiPath stock: CEO share sale filing puts PATH in focus ahead of a busy week

Google stock taps $4 trillion on Apple Gemini AI deal as “Have-Lots” worries grow
Next Story

Google stock taps $4 trillion on Apple Gemini AI deal as “Have-Lots” worries grow

Go toTop